ClinicalTrials.gg
CompletedNCT05614063X-TOLE2Updated May 14, 2026

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

A Phase 3 interventional study of XEN1101 and Placebo in Focal Onset Seizures, sponsored by Xenon Pharmaceuticals Inc.. Completed at 125 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Xenon Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 395 studies in Seizures with a site in United States — 75 open to participants now, 93 under way, 21 of them phase 3. Seizures · United States.

Enrollment
24th of 306
380 · median 56
Started
2022
with 15 others
Phase 3
84 of 395
15 open now
Registered
324th of 395
by date

Among the 395 studies in Seizures with a site in United States, this one is the 24th largest by enrollment of the 306 interventional ones that give a count, is one of 16 that started in 2022, is one of 84 in phase 3, and was the 324th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

75 of the 395 studies in Seizures with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Seizures with a site in United States, or all of them as a file.
02

Study summary

The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.

Read the detailed description

Approximately 360 subjects will be randomized in a blinded manner to one of two active treatment groups or placebo in a 1:1:1 fashion (XEN1101 25 mg : 15 mg : Placebo). Eligible subjects will have up to 9.5 weeks of baseline to assess frequency of seizures, followed by 12 weeks of blinded treatment. In order to be included in the study, subjects must be treated with a stable dose of 1 to 3 allowable antiseizure medications (ASMs) for at least one month prior to screening, during baseline, and throughout the double-blind treatment period (DBP) of the study. During the DBP, subjects will be instructed to orally take XEN1101 or placebo once daily with an evening meal.

Subjects who complete the 12-week DBP will have the opportunity to qualify and enroll in a separate open-label extension (OLE) study for continued treatment with XEN1101. Subjects who do not enroll in the OLE will enter a 8-week post treatment follow-up period.

03

Conditions studied

  • Focal Onset Seizures

Keywords

  • Epilepsy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be properly informed of the nature and risks of the study and give in writing, prior to entering the study
  • Diagnosis (≥2 years) of focal epilepsy according to the International League Against Epilepsy (ILAE) Classification of Epilepsy (2017). Subject must have had adequate trials of at least 2 ASMs, which were given (and tolerated) at adequate therapeutic doses, without achieving sustained seizure freedom.
  • Treatment with a stable dose of 1 to 3 allowable current ASMs for at least one month prior to screening, during baseline, and throughout the duration of the DBP
  • Able to keep accurate seizure diaries

Exclusion criteria

Exclusion Criteria:

  • Previously documented electroencephalogram which shows any pattern not consistent with focal etiology of seizures.
  • History of focal aware non-motor seizures only, non-epileptic psychogenic seizure, primary generalized seizure, developmental and epileptic encephalopathy, including Lennox-Gastaut syndrome.
  • Seizures secondary to drug or alcohol use, ongoing infection, neoplasia, demyelinating disease, degenerative neurological disease, metabolic illness, progressive structural lesion, encephalopathy, or progressive central nervous system (CNS) disease.
  • History of status epilepticus or repetitive seizures within the 12-month period preceding Visit 1 where the individual seizures cannot be counted.
  • History of neurosurgery for seizures \<1 year prior to Visit 1, or radiosurgery \<2 years prior to enrollment.
  • Any medical condition or personal circumstance that, in the opinion of the investigator, exposes the subject to unacceptable risk by participating in the study or prevents adherence to the protocol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
380 participants (actual)

Study arms

  • Experimental
    XEN1101 25 mg/day

    XEN1101 25 mg/day

    Drug: XEN1101

  • Experimental
    XEN1101 15 mg/day

    XEN1101 15 mg/day

    Drug: XEN1101

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • XEN1101 Capsules

    Also known as: Azetukalner

  • DrugPlacebo

    Placebo Capsules

06

What researchers measure

Primary outcomes

  1. Median percent change (MPC) in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo.

    Time frame: From baseline through to the double blind period (week 12)

Secondary outcomes

  1. Proportion of subjects experiencing ≥50% reduction in monthly (28 days) focal seizure frequency from baseline through the DBP for XEN1101 versus placebo.

    Time frame: From baseline through to the double blind period (week 12)

  2. MPC in weekly (7 days) focal seizure frequency from baseline to Week 1 for XEN1101 versus placebo.

    Time frame: From baseline through to the week 1

  3. Proportion of subjects experiencing "at least much improved" (including "much" and "very much improved") in Patient Global Impression of Change (PGI-C).

    Time frame: From baseline through to the double blind period (week 12)

  4. To assess adverse events as criteria for safety and tolerability of XEN1101

    Time frame: From screening through to 56 days post-final dose.

07

Study locations

125 sites
  • Strada Patient Care Center
    Mobile, Alabama 36604, United States
  • Xenoscience
    Phoenix, Arizona 85004, United States
  • University of Arizona, Health Sciences Center
    Tucson, Arizona 85724, United States
  • Clinical Trials, Inc
    Little Rock, Arkansas 72205, United States
  • Brain Science Research Institute
    Los Angeles, California 90025, United States
  • University of California, David Clinical & Translational Science Center Clinical Research (CCRC)
    Sacramento, California 95817, United States
  • Anschutz Health Sciences
    Aurora, Colorado 80011, United States
  • Serenity Research
    Miami, Florida 33176, United States
  • Research Institute of Orlando, LLC
    Orlando, Florida 32806, United States
  • Panhandle Research & Medical Clinic
    Pensacola, Florida 32503, United States
  • Medsol Clinical Research Center
    Port Charlotte, Florida 33952, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Encore Medical Research of Weston, LLC
    Weston, Florida 33021, United States
  • Emory Brain Health Center
    Atlanta, Georgia 30329, United States
  • Hawaii Pacific Neuroscience
    Honolulu, Hawaii 96817, United States
  • Consultants in Epilepsy and Neurology
    Boise, Idaho 83702, United States
  • Indiana University, IU Health Partners, Adult Neurology Clinic
    Indianapolis, Indiana 46202, United States
  • The University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Bluegrass Epilepsy Research, LLC
    Lexington, Kentucky 40504, United States
  • University of Kentucky, Dept. of Neurology
    Lexington, Kentucky 40536-0284, United States
  • MaineHealth Neurology - Scarborough
    Scarborough, Maine 04074, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Medstar Franklin Square Medical Center
    Baltimore, Maryland 21237, United States
  • Mid-Atlantic Epilepsy and Sleep Center
    Bethesda, Maryland 20817, United States
  • MedStar Georgetown University Hospital
    Clinton, Maryland 20735, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Michigan State University
    East Lansing, Michigan 48824, United States
  • Cornwell Health
    Grand Rapids, Michigan 49506, United States
  • Minneapolis Clinic of Neurology
    Burnsville, Minnesota 55337, United States
  • Saint Louis University Medical School - Neurosciences Clinical Research Unit
    St Louis, Missouri 63104, United States
  • Washington University, St. Louis
    St Louis, Missouri 63110, United States
  • Northeast Epilepsy Group
    Hackensack, New Jersey 07601, United States
  • Dent Neurosciences Research Center
    Buffalo, New York 14226, United States
  • NYU Comprehensive Epilepsy Center (CEC)
    New York, New York 10016, United States
  • Weill Cornell Medicine/ New York-Presbyterian Hospital
    New York, New York 10021, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Montefiore Medical Center
    The Bronx, New York 10467-2401, United States
  • Onsite Clinical Solutions, LLC
    Charlotte, North Carolina 28211, United States
  • Duke Neurology
    Durham, North Carolina 27713, United States
  • Meridian Clinical Research, LLC
    Raleigh, North Carolina 27607, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • Summa Health
    Akron, Ohio 44304, United States
  • Providence Brain & Spine Institute
    Portland, Oregon 97225, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140-4105, United States
  • Austin Epilepsy Care Center (AECC)
    Austin, Texas 78758, United States
  • ANESC Research
    El Paso, Texas 79912, United States
  • UT Physicians Epilepsy Clinic
    Houston, Texas 77030, United States
  • UT Health San Antonio
    San Antonio, Texas 78229, United States
  • Carilion Clinic - Neurology
    Roanoke, Virginia 24013, United States
  • Sentara Neurology Specialists
    Virginia Beach, Virginia 23456, United States
  • University of Washington Main Hospital
    Seattle, Washington 98104, United States
  • Aurora St. Luke's Medical Center
    Milwaukee, Wisconsin 53215, United States
  • INECO and Favoloro Fundation
    Buenos Aires, 1060, Argentina
  • Hospital General de Agudos J.M. Ramos Mejia
    Buenos Aires, 1221, Argentina
  • Hospital De Alta Complejidad en Red el Cruce Nestor Kirchner - SAMIC
    Buenos Aires, B1888AAE, Argentina
  • STAT Research S.A.
    Buenos Aires, C1023AAB, Argentina
  • Hospital Italiano
    Buenos Aires, C1199ABB, Argentina
  • CENyR
    Caba, C1424, Argentina
  • Hospital Córdoba
    Córdoba, CP 5000, Argentina
  • Sanatorio del Sur S.A.
    San Miguel de Tucumán, 4000, Argentina
  • St Vincent's Hospital Melbourne
    Fitzroy, Melbourne 3065, Australia
  • Royal Prince Alfred Hospital (RAPH)
    Camperdown, New South Wales 2050, Australia
  • Prince of Wales Hospital
    Sydney, New South Wales 2031, Australia
  • Southern Neurology
    Sydney, New South Wales 2217, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • The University of Queensland (UQ) - Mater Research Institute (MRI)
    Brisbane, Queensland 4101, Australia
  • Austin Health Pharmacy Clinical Trials
    Heidelberg, Victoria 3079, Australia
  • The Alfred Hospital (Alfred Health)
    Melbourne, Victoria 3004, Australia
  • The Royal Melbourne Hospital
    Melbourne, 3052, Australia
  • MHAT Puls AD
    Blagoevgrad, 2700, Bulgaria
  • Center For Neurologic Research
    Lethbridge, Alberta T1J 0N9, Canada
  • London Health Sciences Centre
    London, Ontario N6A 5A5, Canada
  • Le Centre Hospitalier de l'Universite' de Montreal (CHUM)
    Montreal, Quebec H2X3E4, Canada
  • Centro de investigación Clinica UC
    Santiago, 833073, Chile
  • Hospital Clínico Vina del Mar
    Viña del Mar, 2520612, Chile
  • FORBELI s.r.o., Neurologicka ambulance
    Prague, 160-00, Czechia
  • American Hospital Network LLC
    Tbilisi, 0121, Georgia
  • Institute of Neurology and Neuropsychology
    Tbilisi, 0186, Georgia
  • Epilepsy Center Bethel
    Bielefeld, 33617, Germany
  • Universitatsklinikum Bonn
    Bonn, Germany
  • Epilepsiezentrum Frankfurt Rhein-Main
    Frankfurt, 60528, Germany
  • University Medical Center Freiburg
    Freiburg im Breisgau, 79106, Germany
  • Philipps-Universität Marburg
    Marburg, 35043, Germany
  • LMU Munich, Department of Neurology
    Munich, 81277, Germany
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
  • Universitatsklinik fur neurologie, universitats - und Rehabilitationskliniken Ulm
    Ulm, 89081, Germany
  • Beaumont Hospital
    Dublin, D09 YD60, Ireland
  • Istituto delle Scienze Neurologiche di Bologna
    Bologna, 40139, Italy
  • Università Degli Studi Gabriele d'Annunzio Di Chieti
    Pescara, 66100, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, 56100, Italy
  • Azienda Ospedaliero-Universitaria Policlinico Umberto I
    Rome, 00186, Italy
  • Pauls Stradina Clinical university hospital
    Riga, LV-1002, Latvia
  • Riga East University Hospital
    Riga, LV-1024, Latvia
  • Human Science Research Trials S. de R.L. de C.V.
    Mexico City, 14050, Mexico
  • Neurocencias Esudios Clinicos SC
    Sinaloa, 80020, Mexico
  • University of Auckland
    Auckland, 1023, New Zealand

Showing the first 100 of 125 sites across 18 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Jan 2026, 37 months.

Of 43 industry-sponsored phase 3 interventional studies under Seizures, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 79. This study's 37 months is below that.

Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 33 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2022
First posted
Nov 14, 2022
StartActual
Nov 18, 2022
Primary completionActual
Jan 12, 2026
CompletionActual
Feb 3, 2026
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05614063
Collaborators
Worldwide Clinical Trials
Responsible party
Sponsor
First posted
Nov 14, 2022
Start date
Nov 18, 2022
Primary completion
Jan 12, 2026
Completion
Feb 3, 2026
Last update
May 14, 2026

Study contacts

Medical Director
study director · Xenon Pharmaceuticals Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: XEN1101

Start the discussion